• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser241Ala (c.721T>G); ClinVar=VCV000376665; Zygosity=Homozygous (Cosmic-CLP=1287381; DepMap=ACH-002089).
  

PubMed=9816093
Kasprzyk P.G., Sullivan T.L., Hunt J.D., Gubish C.T., Scoppa C.A., Oelkuct M., Bird R.E., Fischer P.H., Siegfried J.M., King C.R.
Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification.
Clin. Cancer Res. 2:75-80(1996)

PubMed=9816140
Skrepnik N., Araya J.C., Qian Z., Xu H.-B., Hamide J., Mera R., Hunt J.D.
Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice.
Clin. Cancer Res. 2:1851-1857(1996)

PubMed=10545285; DOI=10.1006/pupt.1999.0210
Siegfried J.M., Krishnamachary N., Gaither Davis A.L., Gubish C.T., Hunt J.D., Shriver S.P.
Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer.
Pulm. Pharmacol. Ther. 12:291-302(1999)

PubMed=15735034; DOI=10.1158/0008-5472.CAN-04-1872
Stabile L.P., Lyker J.S., Gubish C.T., Zhang W.-P., Grandis J.R., Siegfried J.M.
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Cancer Res. 65:1459-1470(2005)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)